Amino Blend's clinical logic operates through two converging functional pairs — each pair addressing a distinct biological system, and both systems being fundamental to physical performance, recovery, and overall health:

The nitric oxide pair (Arginine + Citrulline) — vascular performance and circulation: Arginine provides immediate NO synthesis substrate; citrulline maintains sustained arginine availability through the renal recycling pathway. Together they support robust, sustained nitric oxide production — improving vascular tone, circulatory efficiency, oxygen and nutrient delivery to peripheral tissues, and the cardiovascular and performance benefits that depend on healthy endothelial NO signaling. Neither active alone provides both immediate substrate and sustained recycling simultaneously — the combination is more effective than either in isolation.

The collagen pair (Lysine + Proline) — structural integrity and tissue repair: Proline provides the primary structural residues of the collagen triple helix; lysine provides the crosslinking residues that stabilize collagen fibril assembly. Together they supply the two most critical amino acid substrates for collagen synthesis — supporting connective tissue integrity, exercise-induced tissue remodeling, wound healing, and the structural protein production that healthy joints, tendons, ligaments, skin, and vasculature require. Again, the combination addresses complementary and non-redundant dimensions of the same biosynthetic process.

Cross-pair synergy — the vascular-structural connection: The arginine-citrulline pair doesn't only support exercise performance — improved nitric oxide-mediated circulation also enhances the delivery of the lysine and proline supplied by the collagen pair to the connective tissues and repair sites where they are needed. Better vascular function means better amino acid delivery to remodeling tissue; better connective tissue integrity means more structurally sound vessels and muscle support structures. The two functional pairs support each other through this circulatory-structural connection.

Injectable delivery maximizes all four components: Amino acids administered orally undergo significant first-pass intestinal and hepatic catabolism — arginine in particular is substantially degraded by intestinal arginase before reaching systemic circulation, limiting the bioavailability of oral arginine supplementation. Subcutaneous or intramuscular injection bypasses this first-pass catabolism entirely, delivering all four amino acids to systemic circulation at the concentrations compounded into the formula, without the absorption variability that limits oral supplementation efficacy.

With consistent administration as part of a provider-supervised protocol:

Support for nitric oxide production through the arginine-citrulline precursor and recycling pathway — improving vascular dilation, blood flow, and peripheral oxygen and nutrient delivery

Improved cardiovascular efficiency and endothelial function through sustained NO signaling

Enhanced physical performance and endurance through improved muscular oxygen delivery and reduced exercise-induced fatigue

Support for collagen synthesis through paired lysine-proline substrate delivery — promoting connective tissue integrity in tendons, ligaments, cartilage, skin, and vasculature

Accelerated tissue repair and recovery from exercise-induced micro-damage through improved connective tissue remodeling substrate availability

Support for ammonia detoxification through arginine's role in the hepatic urea cycle — relevant during high protein turnover states

Carnitine synthesis support through lysine as a carnitine precursor — linking this formula to mitochondrial fatty acid metabolism and energy production

Improved amino acid delivery compared to oral supplementation through injectable bypass of first-pass intestinal and hepatic catabolism

Support for energy metabolism, metabolic rate, and body composition as part of a comprehensive wellness protocol

Mood and sleep support through amino acid precursor availability relevant to neurotransmitter synthesis

Results vary by individual, baseline amino acid status, activity level, dietary protein intake, and concurrent health conditions. Amino Blend Injection is a supplemental amino acid support tool — it is most effective as part of a comprehensive nutrition and wellness program. It is not a standalone treatment for any specific condition.

Amino Blend Injection is a prescription-only compounded injectable medication. Discuss your complete medication list and health history with your provider and pharmacist before initiating therapy.

Do not start, stop, or change the dose of any medication without consulting your healthcare provider.

Stop use and contact your provider immediately if you experience any of the following:

Signs of allergic reaction: Rash, hives, itching, red or blistered skin with or without fever, wheezing, chest or throat tightness, difficulty breathing, swallowing, or talking, unusual hoarseness, or swelling of the face, lips, tongue, or throat. Seek emergency care if severe.

Signs of fluid and electrolyte problems: Mood changes, confusion, muscle pain or weakness, irregular heartbeat, severe dizziness or fainting, rapid heartbeat, increased thirst, seizures, severe fatigue or weakness, loss of appetite, changes in urination volume or inability to urinate, dry mouth, dry eyes, or severe nausea and vomiting.

Signs of elevated ammonia levels: Irregular heartbeat, abnormal breathing, confusion, pale skin, slow heartbeat, seizures, excessive sweating, vomiting, or muscle twitching. High ammonia can occur if the urea cycle is impaired — relevant in patients with hepatic or urea cycle disorders.

Signs of liver problems: Dark urine, fatigue, loss of appetite, nausea or abdominal pain, light-colored stools, vomiting, or jaundice (yellowing of skin or eyes).

Signs of blood pressure changes: Severe headache or dizziness, fainting, or visual changes.

Cyanosis: Bluish discoloration of the lips, nail beds, fingers, or toes — indicating reduced oxygen delivery; seek immediate medical evaluation.

Other symptoms requiring prompt evaluation: Excessive sweating, shortness of breath, significant unexplained weight gain, swelling in the arms or legs, chest pain, fever, or chills.

Contraindications and special precautions:

Herpes simplex virus (HSV) — active or recurrent: Arginine is a known trigger for HSV replication — the herpes virus uses arginine for viral protein synthesis, and elevated arginine availability can precipitate or worsen outbreaks in susceptible individuals. Patients with a history of oral or genital herpes should discuss this with their provider before initiating arginine-containing therapy. Note that lysine has historically been used to counteract arginine's HSV-stimulating effect; its presence in this formula may provide partial mitigation, but this should be discussed individually with your provider.

Cardiovascular disease — recent myocardial infarction: A clinical trial evaluating high-dose arginine supplementation following myocardial infarction was stopped early due to increased adverse events in the arginine group. Patients with a recent history of myocardial infarction should not use arginine-containing injectables without cardiologist evaluation and explicit guidance.

Urea cycle disorders: Arginine participates in the urea cycle. Patients with known or suspected urea cycle enzyme deficiencies are at risk for hyperammonemia with amino acid loading and should not use this formula without specialist evaluation.

Renal impairment: Multiple components are renally excreted. Patients with significant renal impairment should discuss dose appropriateness with their provider.

Hepatic impairment: Arginine metabolism and urea cycle function are hepatically dependent. Patients with significant hepatic disease require individualized clinical evaluation before initiating amino acid injection therapy.

Pregnancy and breastfeeding: Safety of this specific combination at injectable concentrations during pregnancy and lactation has not been established. Discuss with your provider.

Antihypertensive medications: Arginine and citrulline promote vasodilation through nitric oxide production — additive blood pressure lowering effects are possible with concurrent antihypertensive medications. Inform all providers of Amino Blend use; blood pressure monitoring is appropriate.

Phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil): PDE5 inhibitors potentiate nitric oxide-mediated vasodilation. Concurrent use with arginine and citrulline may produce additive hypotensive effects; discuss with your provider before combining.

Nitrates (nitroglycerin, isosorbide): Similar mechanism — additive vasodilation and hypotensive risk with arginine-citrulline combination. Use with caution and provider oversight.

Potassium-sparing diuretics or medications affecting potassium: Arginine HCl can affect potassium levels; patients on potassium-sparing diuretics, ACE inhibitors, or ARBs should have electrolytes monitored.

Anticoagulants and antiplatelet medications: Arginine's vascular effects may have modest interactions with anticoagulant therapy; inform your provider and monitor as appropriate.

Lysine and antiviral medications for HSV: Patients on antivirals for herpes simplex should inform their provider of arginine-containing therapy; the arginine-lysine balance and concurrent antiviral coverage should be clinically managed.

Diabetes medications and insulin: Arginine stimulates both insulin and glucagon release — patients on insulin or oral antidiabetic medications should monitor blood glucose and inform their provider of Amino Blend use.

Antihypertensive medications: Arginine and citrulline promote vasodilation through nitric oxide production — additive blood pressure lowering effects are possible with concurrent antihypertensive medications. Inform all providers of Amino Blend use; blood pressure monitoring is appropriate.

Phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil): PDE5 inhibitors potentiate nitric oxide-mediated vasodilation. Concurrent use with arginine and citrulline may produce additive hypotensive effects; discuss with your provider before combining.

Nitrates (nitroglycerin, isosorbide): Similar mechanism — additive vasodilation and hypotensive risk with arginine-citrulline combination. Use with caution and provider oversight.

Potassium-sparing diuretics or medications affecting potassium: Arginine HCl can affect potassium levels; patients on potassium-sparing diuretics, ACE inhibitors, or ARBs should have electrolytes monitored.

Anticoagulants and antiplatelet medications: Arginine's vascular effects may have modest interactions with anticoagulant therapy; inform your provider and monitor as appropriate.

Lysine and antiviral medications for HSV: Patients on antivirals for herpes simplex should inform their provider of arginine-containing therapy; the arginine-lysine balance and concurrent antiviral coverage should be clinically managed.

Diabetes medications and insulin: Arginine stimulates both insulin and glucagon release — patients on insulin or oral antidiabetic medications should monitor blood glucose and inform their provider of Amino Blend use.

Refrigerate at 36°F – 46°F (2°C – 8°C)

Do not freeze

Protect from light; store in original packaging between uses

Keep container tightly sealed

Inspect solution before each use — discard if cloudy, particulate, or abnormally discolored

Keep out of reach of children

For single patient use only — do not share vials